CN101855336B - 含艰难梭菌类毒素a和b的药物组合物 - Google Patents

含艰难梭菌类毒素a和b的药物组合物 Download PDF

Info

Publication number
CN101855336B
CN101855336B CN200880116603.0A CN200880116603A CN101855336B CN 101855336 B CN101855336 B CN 101855336B CN 200880116603 A CN200880116603 A CN 200880116603A CN 101855336 B CN101855336 B CN 101855336B
Authority
CN
China
Prior art keywords
composition
toxoid
vaccine composition
toxoids
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880116603.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101855336A (zh
Inventor
C·R·米道夫
R·法尔纳
P·恰拉梅塔罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Biologics LLC
Original Assignee
Sanofi Pasteur Biologics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics LLC filed Critical Sanofi Pasteur Biologics LLC
Priority to CN201610227574.1A priority Critical patent/CN106039299A/zh
Publication of CN101855336A publication Critical patent/CN101855336A/zh
Application granted granted Critical
Publication of CN101855336B publication Critical patent/CN101855336B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
CN200880116603.0A 2007-09-14 2008-09-15 含艰难梭菌类毒素a和b的药物组合物 Active CN101855336B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610227574.1A CN106039299A (zh) 2007-09-14 2008-09-15 含艰难梭菌类毒素a和b的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97249607P 2007-09-14 2007-09-14
US60/972496 2007-09-14
PCT/US2008/010767 WO2009035707A1 (en) 2007-09-14 2008-09-15 Pharmaceutical compositions containing clostridium difficile toxoids a and b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610227574.1A Division CN106039299A (zh) 2007-09-14 2008-09-15 含艰难梭菌类毒素a和b的药物组合物

Publications (2)

Publication Number Publication Date
CN101855336A CN101855336A (zh) 2010-10-06
CN101855336B true CN101855336B (zh) 2019-07-30

Family

ID=40452372

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880116603.0A Active CN101855336B (zh) 2007-09-14 2008-09-15 含艰难梭菌类毒素a和b的药物组合物
CN201610227574.1A Pending CN106039299A (zh) 2007-09-14 2008-09-15 含艰难梭菌类毒素a和b的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610227574.1A Pending CN106039299A (zh) 2007-09-14 2008-09-15 含艰难梭菌类毒素a和b的药物组合物

Country Status (21)

Country Link
US (3) US9320790B2 (cg-RX-API-DMAC7.html)
EP (3) EP4537849A3 (cg-RX-API-DMAC7.html)
JP (3) JP5503543B2 (cg-RX-API-DMAC7.html)
KR (2) KR101679812B1 (cg-RX-API-DMAC7.html)
CN (2) CN101855336B (cg-RX-API-DMAC7.html)
AU (1) AU2008299885C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816790A8 (cg-RX-API-DMAC7.html)
CA (1) CA2699435A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119979T1 (cg-RX-API-DMAC7.html)
DK (1) DK2198007T3 (cg-RX-API-DMAC7.html)
ES (2) ES3001561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180054T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037932T2 (cg-RX-API-DMAC7.html)
IL (1) IL204366A (cg-RX-API-DMAC7.html)
MX (1) MX2010002815A (cg-RX-API-DMAC7.html)
NO (1) NO2198007T3 (cg-RX-API-DMAC7.html)
PL (1) PL2198007T3 (cg-RX-API-DMAC7.html)
PT (1) PT2198007T (cg-RX-API-DMAC7.html)
RU (1) RU2550271C2 (cg-RX-API-DMAC7.html)
SI (1) SI2198007T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009035707A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180054T1 (hr) 2007-09-14 2018-02-09 Sanofi Pasteur Biologics, Llc Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
ES2968629T3 (es) * 2011-04-22 2024-05-13 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
HRP20190711T1 (hr) 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni pripravak
CN111729077A (zh) 2013-03-14 2020-10-02 武田疫苗股份有限公司 减毒活甲病毒制剂的组合物和方法
CA2907156A1 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxins, compositions and related methods
BR112015023332A2 (pt) * 2013-03-15 2017-08-22 Sanofi Pasteur Inc Toxóide, composições e método relacionados
EP3007724B1 (en) * 2013-06-14 2023-07-05 Sanofi Pasteur Inc. Compositions and methods of immunizing against c. difficile
BR112015031541A2 (pt) * 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
US9930893B2 (en) * 2014-02-10 2018-04-03 The Johns Hopkins University Inhibitors of DXP synthase and methods of use thereof
UA122673C2 (uk) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Антитіло, що специфічно зв'язується з людським il-6
US20180110849A1 (en) 2015-05-15 2018-04-26 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
KR20180116359A (ko) 2016-02-23 2018-10-24 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 제제 및 이의 용도
PL3432916T3 (pl) 2016-09-13 2020-04-30 Allergan, Inc. Niebiałkowo stabilzowane kompozycje toksyny clostridium
ES2986389T3 (es) * 2018-05-21 2024-11-11 Chugai Pharmaceutical Co Ltd Formulación liofilizada sellada en un vial de vidrio
EP4168032A2 (en) * 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5624914A (en) * 1991-10-16 1997-04-29 Schering Corporation Lipophilic oligosaccharide antibiotic salt compositions
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
CN1195993A (zh) * 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
CN1298306A (zh) * 1998-05-28 2001-06-06 辛索尔布生物技术有限公司 艰难梭菌毒素b相关疾病的治疗
US6544518B1 (en) * 1999-04-19 2003-04-08 Smithkline Beecham Biologicals S.A. Vaccines
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
AU4646393A (en) 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
EP0892054B1 (en) * 1997-06-20 2006-11-29 Intervet International BV Clostridium perfringens vaccine
DE69829400T2 (de) * 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
EP1568378B1 (en) * 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
JP2000117967A (ja) * 1998-10-16 2000-04-25 Fuji Photo Film Co Ltd インクジェット記録方法
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
US6599715B1 (en) * 1999-05-12 2003-07-29 The Regents Of The University Of California Real time viability detection of bacterial spores
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
WO2003088946A1 (en) * 2002-04-19 2003-10-30 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2005035573A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液の安定化方法
CN102139099A (zh) * 2004-07-26 2011-08-03 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物
JP2008515996A (ja) * 2004-10-13 2008-05-15 イリプサ， インコーポレイテッド 毒素結合性オリゴ糖および重合体粒子を含有する医薬組成物
FR2881139A1 (fr) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech Composition pour la lyophilisation de proteines
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
BRPI0613001B8 (pt) 2005-10-06 2021-05-25 Allergan Inc composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína
WO2007044809A2 (en) * 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
EP2086581B1 (en) 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
HRP20180054T1 (hr) 2007-09-14 2018-02-09 Sanofi Pasteur Biologics, Llc Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b
JP2012510497A (ja) * 2008-12-03 2012-05-10 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング ワクチンの生産方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5624914A (en) * 1991-10-16 1997-04-29 Schering Corporation Lipophilic oligosaccharide antibiotic salt compositions
CN1195993A (zh) * 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
CN1298306A (zh) * 1998-05-28 2001-06-06 辛索尔布生物技术有限公司 艰难梭菌毒素b相关疾病的治疗
US6544518B1 (en) * 1999-04-19 2003-04-08 Smithkline Beecham Biologicals S.A. Vaccines

Also Published As

Publication number Publication date
IL204366A (en) 2013-02-28
US20110045025A1 (en) 2011-02-24
SI2198007T1 (en) 2018-04-30
WO2009035707A1 (en) 2009-03-19
EP2198007B1 (en) 2017-10-25
US9687541B2 (en) 2017-06-27
RU2010114730A (ru) 2011-10-20
ES3001561T3 (en) 2025-03-05
KR20160005378A (ko) 2016-01-14
JP2010539172A (ja) 2010-12-16
PT2198007T (pt) 2018-01-29
MX2010002815A (es) 2010-07-30
KR101679812B1 (ko) 2016-11-28
DK2198007T3 (en) 2018-01-15
WO2009035707A9 (en) 2010-06-10
EP2198007A1 (en) 2010-06-23
CN106039299A (zh) 2016-10-26
ES2657485T3 (es) 2018-03-05
US20160317640A1 (en) 2016-11-03
HRP20180054T1 (hr) 2018-02-09
KR20100075912A (ko) 2010-07-05
CA2699435A1 (en) 2009-03-19
EP4537849A2 (en) 2025-04-16
CY1119979T1 (el) 2018-12-12
EP2198007A4 (en) 2012-03-07
JP6258674B2 (ja) 2018-01-10
JP5503543B2 (ja) 2014-05-28
JP2014055174A (ja) 2014-03-27
BRPI0816790A8 (pt) 2017-05-16
EP3124044B1 (en) 2024-12-18
AU2008299885B2 (en) 2014-12-11
US20180000920A1 (en) 2018-01-04
EP3124044C0 (en) 2024-12-18
AU2008299885C1 (en) 2015-06-25
CN101855336A (zh) 2010-10-06
AU2008299885A1 (en) 2009-03-19
HUE037932T2 (hu) 2018-09-28
JP2017052773A (ja) 2017-03-16
EP4537849A3 (en) 2025-07-09
RU2550271C2 (ru) 2015-05-10
BRPI0816790A2 (pt) 2014-10-14
PL2198007T3 (pl) 2018-03-30
EP3124044A1 (en) 2017-02-01
US9320790B2 (en) 2016-04-26
US10639362B2 (en) 2020-05-05
NO2198007T3 (cg-RX-API-DMAC7.html) 2018-03-24
EP3124044B8 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
CN101855336B (zh) 含艰难梭菌类毒素a和b的药物组合物
CN101443038B (zh) 尼古丁-载体疫苗制剂
Hassett et al. Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants
CA3097058A1 (en) Additives for protein formulations to improve thermal stability
CN112516090A (zh) 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
KR20210113271A (ko) 콜라게나제 제형 및 이의 제조 방법
EP2515934B1 (en) Vaccine compositions
Mensch et al. Enabling lyophilized pneumococcal conjugate vaccines through formulation design and excipient selection suitable for a multivalent adjuvanted vaccine
US20100040625A1 (en) Pharmaceutical Compositions Containing Monoclonal Anti-Idiotypic Anti-Ca-125 Antibody and Aluminium Derivatives
HK1230484A1 (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
AU2015201233B2 (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
HK1147285A (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
Panton Surfactant selection in biopharmaceutical product development

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147285

Country of ref document: HK

CB02 Change of applicant information

Address after: Delaware

Applicant after: ACAMBIS INC

Address before: Massachusetts

Applicant before: Acambis Inc.

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1147285

Country of ref document: HK